Mitonafide

Mitonafide

SCHEMBL29499462

CN(C)CCN1C(=O)c2cccc3cc([N+](=O)[O-])cc(c23)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 4/20 1.00
PABPC1 P11940 3/20 1.00
HEXA P06865 1/20 0.67
HEXB P07686 1/20 0.67
POLB P06746 5/20 0.67
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
RAD52 P43351 2/20 0.67
KDM4E B2RXH2 1/20 0.67
MAPT P10636 1/20 0.67
S1PR1 P21453 1/20 0.67
HTT P42858 1/20 0.67
RECQL P46063 1/20 0.67
RAB9A P51151 1/20 0.67
PAX8 Q06710 1/20 0.67
CYP2D6 P10635 1/20 0.67
LCK P06239 1/20 0.66
CA12 O43570 3/20 0.61
CA1 P00915 3/20 0.61
CA2 P00918 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mitonafide SCHEMBL29352711 1.00 FTO (1.00) FTOPABPC1HEXAHEXBPOLB
Mitonafide SCHEMBL62046 1.00 FTO (1.00) FTOPABPC1HEXAHEXBPOLB
Mitonafide SCHEMBL5166813 0.99 FTO (0.98) FTOPABPC1HEXAHEXBPOLB
Mitonafide SCHEMBL5781995 0.94 FTO (0.88) FTOPABPC1HEXAHEXBPOLB
SCHEMBL11441990 0.93 PABPC1 (0.87) FTOPABPC1HEXAHEXBPOLB
SCHEMBL9504075 0.93 FTO (0.87) FTOPABPC1HEXAHEXBPOLB
SCHEMBL2989147 0.92 FTO (0.85) FTOPABPC1HEXAHEXBPOLB
SCHEMBL7712243 0.90 FTO (0.81) FTOPABPC1HEXAHEXBPOLB
SCHEMBL9501524 0.89 FTO (0.80) FTOPABPC1HEXAHEXBPOLB
SCHEMBL11550721 0.88 FTO (0.79) FTOPABPC1HEXAHEXBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11369613-B2 Salts and solid form of a BTK inhibitor PRINCIPIA BIOPHARMA INC. (US) 2022-06-28 US disclosed
CN-114206848-A Substituted cycloalkyl compounds as modulators of integrated stress pathways 卡里科生命科学有限责任公司 2022-03-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11369613-B2 Salts and solid form of a BTK inhibitor BTK, SYK, JAK1 FTO 2744/4885PABPC1 2798/4885HEXA 4526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.